Trials / Completed
CompletedNCT02363868
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 186 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
Conditions
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2015-02-16
- Last updated
- 2015-07-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02363868. Inclusion in this directory is not an endorsement.